Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001172661-25-003249
Filing Date
2025-08-14
Accepted
2025-08-14 08:01:03
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 8847
  Complete submission text file 0001172661-25-003249.txt   10544
Mailing Address 6200 LOOKOUT ROAD BOULDER CO 80301
Business Address 6200 LOOKOUT ROAD BOULDER CO 80301 720-647-8519
Enliven Therapeutics, Inc. (Subject) CIK: 0001672619 (see all company filings)

EIN.: 811523849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-91465 | Film No.: 251214450
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 16 PALACE STREET LONDON X0 SW1E 5JD
Business Address 16 PALACE STREET LONDON X0 SW1E 5JD 02072272700
Polar Capital Holdings Plc (Filed by) CIK: 0001837309 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 0331
Type: SCHEDULE 13G